Connect with us

Headlines

Lens and Frame Maker Names CEO

He began the role on Feb. 1.

mm

Published

on

MUNICH – The Rodenstock Group, a manufacturer of ophthalmic lenses and frames, has named Anders Hedegaard as its CEO.

The appointment was effective Feb. 1. He follows Oliver Kastalio, who has led the company since 2010 and will take on a new professional challenge.

Podcast: What the Heck is Marketing? And What Should ECPs Focus on to Attract New Clients?
INVISION Podcast

Podcast: What the Heck is Marketing? And What Should ECPs Focus on to Attract New Clients?

Podcast: More Ways to Motivate Your Own Eyecare Business Team
INVISION Podcast

Podcast: More Ways to Motivate Your Own Eyecare Business Team

Podcast: Why Can’t We All Just Get Along?
INVISION Podcast

Podcast: Why Can’t We All Just Get Along?

Hedegaard joins from the GN Store Nord A/S in Denmark, where he was CEO of GN Hearing, a producer of hearing aid technologies. Hedegaard has a broad background in the global life science and healthcare sector.

“I’m delighted to join Rodenstock as CEO,” Hedegaard said. “The company has a long tradition and strong reputation. It manufactures and distributes world-class products, utilizing most innovative technologies and has a huge growth potential.”

Kastalio stated: “I have successfully managed Rodenstock’s turnaround over the past years and set the course for further growth in the eye health sector through the introduction of leading technologies like DNEye. Now is the time to hand over management with a clear conscience.”

Founded in 1877 with its headquarters in Munich, Rodenstock employs around 4,900 people worldwide and is represented with sales offices and distribution partners in more than 85 countries. It maintains production plants at 15 locations in 13 countries.

Advertisement

Since launching in 2014, INVISION has won 21 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY HOYA

Hoya: The Right Lenses for Sun Protection

Eye safety has never been more important--or fashionable. Check out Hoya's Serenity photochromic and Coppertone(R) polarized lens collections, just in time for summer!

Promoted Headlines

Headlines

Ophthalmologists Hope to Undo State Law That Allows ODs to Perform Eye Surgery

They’re attempting a ballot referendum.

mm

Published

on

A movement is afoot in Arkansas to undo recently passed state legislation that allows optometrists to perform certain surgeries.

It’s being led by Safe Surgery Arkansas, a group of medical doctors, Talk Business & Politics reports. They hope to use a ballot referendum to accomplish their goal.

R. Scott Lowery, president of the Arkansas Ophthalmological Society, was quoted saying: “Every day the people of Arkansas rely on medical doctors who have the experience and training to perform medical procedures to ensure that they are getting world class healthcare in Arkansas. We are confident that when the people are heard on this issue, they will not allow individuals without medical degrees and without surgical residencies to jeopardize the precious eyesight of Arkansans.”

The legislation was signed into law in March. The procedures that it allows optometrists to perform include selective laser trabeculoplasty and Nd:YAG laser procedures, along with injections (excluding intravenous and intraocular), removal of lid lesions and chalazion incision and curettage.

Advertisement

The bill called on the Arkansas Board of Optometry to establish credentialing requirements for optometrists to perform these laser procedures, as well as require those doctors to report the outcomes of their procedures to the board.

Vicki Farmer, executive director of the Arkansas Optometry Association, was quoted noting that Arkansas legislators “overwhelmingly approved this measure during the recent session, after listening to hours of testimony and debate, and learning optometrists in other states, like Oklahoma, have been safely performing these procedures for more than 20 years.”

Read more at Talk Business & Politics

Continue Reading

Headlines

Eye Doctors Can Play a Key Role in Diagnosing Gut Disease

About 3.1 million people in the U.S. have IBD, which includes Crohn’s disease and ulcerative colitis.

mm

Published

on

Optometrists can play an important role in helping patients who have inflammatory bowel disease, the American Optometric Association reports.

Inflammatory bowel disease can cause symptoms in the eye, which ODs can detect during during comprehensive eye examinations, according to a newly released AOA Health Policy Institute brief.

“Given that comprehensive eye examinations can lead to earlier, definitive diagnosis of IBD, patient outcomes improve with earlier treatment,” AOA reports.

“The clinical manifestations of common inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, are not restricted to the gastrointestinal tract,” according to the Health Policy Institute brief. “IBDs have impact to other organs in a significant number of patients, including the eyes in 72.1 percent of patients with IBDs.”

The brief links IBD’s inflammation to a variety of ophthalmic conditions, including:

  • Episcleritis
  • Scleritis
  • Keratoconjunctivitis sicca (dry eye)
  • Retinal edema
  • Optic neuritis (swelling of the optic nerve)
  • Extraocular muscle nerve palsies.

According to the brief, about 3.1 million people in the U.S. have IBD, which includes Crohn’s disease and ulcerative colitis.

“Evaluation of the eye should be a routine component of care in patients with IBD just as it is with similar chronic co-morbid systemic conditions like diabetes,” according to the paper.

Continue Reading

Headlines

Eye Health Firm Acquired in $800M Deal

The acquisition focuses on treatments for inherited retinal disorders.

mm

Published

on

CAMBRIDGE, MA — Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on treatments for inherited retinal disorders.

As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology, according to a press release.

The transaction value was about $800 million. Nightstar’s common stock will no longer be listed for trading on the Nasdaq Global Select Market.

Nightstar is developing adeno-associated virus treatment. Its lead asset is NSR-REP1 for the treatment of choroideremia, a rare degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments. Initially, patients with choroideremia experience poor night vision, and over time progressive visual loss leads to complete blindness.

NSR-RPGR is Nightstar’s second clinical program for the treatment of X-linked retinitis pigmentosa, which is also a rare inherited retinal disease primarily affecting males with no approved treatments. The disease leads to loss of photoreceptor cells, resulting in retinal dysfunction by adolescence and early adulthood, progressing to legal blindness when patients reach their 40s.

“Today marks a significant achievement for Biogen,” said Michel Vounatsos, Biogen’s CEO. “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities. We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

Continue Reading

Advertisement

Advertisement

Advertisement

Most Popular